Structural genomics: bridging functional genomics and structure-based drug design.
Considerable advances in structural genomics have been witnessed in the last year. Several pilot studies have begun to report their initial results, and new centers have been funded to join the endeavor. The legacies of the genome sequencing efforts, namely high-throughput molecular biology and whole-organism genome sequences, have been integrated as front-end modules for structural genomics pipelines. Impressive advances have been made in NMR spectroscopy and X-ray crystallography. New methods in structural bioinformatics and computational chemistry have been published that provide the means to exploit the wealth of new information in drug discovery. Not surprisingly, the biopharmaceutical industry has been quick to recognize the benefits of these new developments and has begun to adopt them. This article reviews recent results from structural genomics initiatives and the potential applications of new information and technologies in the drug discovery process.
Buchanan
Sean G
SG
sean@stromix.com
D015195:Drug Design; D023281:Genomics / Q000379:methods* / Q000639:trends; D006801:Humans; D011487:Protein Conformation / Q000187:drug effects; D013329:Structure-Activity Relationship